Alzheimer's drug Leqembi receives go ahead from the FDA to be used in patients
Eisai achieves FDA approval for it's Alzheimer's disease drug Leqembi, after rigorous testing in clinical trials show it reduces the size of characteristic plaques in the brains of patients.
After many stages of testing and intense review, the Eisai R&D Management drug for Alzheimer’s disease, Leqembi, has been approved by the US FDA.
Leqembi is the brand name for the drug lecanemab-irmb, the second of such drugs to be approved for the treatment of Alzheimer’s by targeting the pathology of the disease, aiming to reduce the amyloid plaques in the brain that are inherent to the disease.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” stated Billy Dunn, Director of the Office of Neuroscience in the FDA’s Centre for Drug Evaluation and Research. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
Leqembi was tested in a Phase III, double-blind, placebo-controlled, parallel-group, dose-finding study, which included 856 patients with Alzheimer’s disease, who had confirmed presence of amyloid beta plaques, identified using positron emission tomography (PET), and mild cognitive impairment.
The test participants were given 10 mg/kg of lecanemab every two weeks. When compared to the control group at 79 weeks post start of treatment, the test subjects showed a statistically significant decrease in amyloid-beta plaques in the brain; the control group demonstrated no reduction in plaque build-up.
These remarkable test results led to the accelerated approval of Leqembi, based on the reduction in plaques after PET in areas of the brain most likely to be affected.
On prescription, Leqembi does come with a warning against amyloid-related imaging abnormalities (ARIA), which can develop with this class of antibodies. ARIA do not regularly give rise to symptoms, but serious and life-threatening adverse events have been known to occur, which did stir up concerns in the testing phase, but were mollified after further investigation. ARIA is commonly characterized by temporary swelling in the some areas of the brain and may also introduce small bleeds on the brain giving rise to symptoms such as headaches, confusion, dizziness, and seizure. The most common side-affects of Leqembi were headaches and ARIA.
The approval of the drug only covers the specific use as was tested in the clinical trial, i.e patients with mild cognitive impairment or mild dementia stage of disease. There is currently no data to show whether there is any difference in safety or efficacy if the drug is used in patients at earlier or later stages of disease progression. This is something that will have to be elucidated in further clinical trials.
Approval granted under Fast Track, Priority Review and Breakthrough Therapy designations is a big achievement in the ongoing battle to find effective treatments for Alzheimer’s disease and is a promising step for testing drugs in this class.
For more big drug approvals to watch out for in 2023, see our recent article on the major drug approvals of recent times here.
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance